Mariano Provencio1, Enric Carcereny2, Delvys Rodríguez-Abreu3, Rafael López-Castro4, María Guirado5, Carlos Camps6, Joaquim Bosch-Barrera7, Rosario García-Campelo8, Ana Laura Ortega-Granados9, José Luis González-Larriba10, Joaquín Casal-Rubio11, Manuel Domine12, Bartomeu Massutí13, María Ángeles Sala14, Reyes Bernabé15, Juana Oramas16, Elvira Del Barco17. 1. Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. 2. Instituto Catalán de Oncología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. 3. Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain. 4. Hospital Clínico Universitario de Valladolid, Valladolid, Spain. 5. Hospital de Elche, Elche, Spain. 6. Hospital General de Valencia, Valencia, Spain. 7. Instituto Catalán de Oncología, Girona, Spain. 8. Hospital Universitario de la Coruña, La Coruña, Spain. 9. Complejo Hospitalario de Jaen, Jaen, Spain. 10. Hospital Universitario Clínico San Carlos, Madrid, Spain. 11. Complejo Hospitalario Universitario de Vigo, Pontevedra, Spain. 12. Hospital Fundación Jiménez Díaz, Madrid, Spain. 13. Hospital Universitario General de Alicante, Alicante, Spain. 14. Hospital de Basurto, Bilbao, Spain. 15. Hospital Universitario Virgen del Rocío, Sevilla, Spain. 16. Hospital Universitario de Canarias, Santa Cruz Tenerife, Spain. 17. Hospital Universitario de Salamanca, Salamanca, Spain.
Abstract
BACKGROUND: Lung cancer remains a leading cause of cancer incidence and mortality worldwide. Although Spain contributes to global statistics related to cancer, it is difficult to discern aspects linked to clinical presentation of the disease or molecular testing. The Thoracic Tumor Registry (TTR) was created with the aim of filling this gap. METHODS: Observational cohort multicenter study performed in Spain, including patients with lung cancer or other types of thoracic tumors undergoing active treatment or palliative care only. Enrollment took place between August 2016 and December 2018. The evaluation included a review of demographic, epidemiological, clinical and molecular data. RESULTS: A total of 6,600 patients diagnosed with non-small cell lung cancer (NSCLC) were recruited at 56 Spanish hospitals. The mean age at diagnosis was 64 years. The majority of patients (80%) presented with advanced disease, being adenocarcinoma the most frequent histological type. Up to 86% of patients were current- or ex-smokers, with men starting to smoke earlier than women (average age 17.9 vs. 19.2 years). Sixty-seven percent of patients underwent some type of molecular testing. Mutations in EGFR and KRAS genes were found in 18% and 28% of patients, respectively. CONCLUSIONS: Our findings suggest that the TTR study accurately describes the clinical reality of lung cancer in Spain, including useful information on smoking status as well as molecular profiling and tumor histology, and can therefore be used to drive improvements in health care. Social and political pressure to reduce tobacco consumption among the population should be reinforced, particularly among youth.
BACKGROUND: Lung cancer remains a leading cause of cancer incidence and mortality worldwide. Although Spain contributes to global statistics related to cancer, it is difficult to discern aspects linked to clinical presentation of the disease or molecular testing. The Thoracic Tumor Registry (TTR) was created with the aim of filling this gap. METHODS: Observational cohort multicenter study performed in Spain, including patients with lung cancer or other types of thoracic tumors undergoing active treatment or palliative care only. Enrollment took place between August 2016 and December 2018. The evaluation included a review of demographic, epidemiological, clinical and molecular data. RESULTS: A total of 6,600 patients diagnosed with non-small cell lung cancer (NSCLC) were recruited at 56 Spanish hospitals. The mean age at diagnosis was 64 years. The majority of patients (80%) presented with advanced disease, being adenocarcinoma the most frequent histological type. Up to 86% of patients were current- or ex-smokers, with men starting to smoke earlier than women (average age 17.9 vs. 19.2 years). Sixty-seven percent of patients underwent some type of molecular testing. Mutations in EGFR and KRAS genes were found in 18% and 28% of patients, respectively. CONCLUSIONS: Our findings suggest that the TTR study accurately describes the clinical reality of lung cancer in Spain, including useful information on smoking status as well as molecular profiling and tumor histology, and can therefore be used to drive improvements in health care. Social and political pressure to reduce tobacco consumption among the population should be reinforced, particularly among youth.
Entities:
Keywords:
Lung cancer; Spain; cancer registry; molecular profiling; smoking status
Authors: William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus Journal: Proc Natl Acad Sci U S A Date: 2004-08-25 Impact factor: 11.205
Authors: Monica Spinola; Peter Meyer; Stefan Kammerer; F Stefania Falvella; Melanie B Boettger; Carolyn R Hoyal; Carmen Pignatiello; Reiner Fischer; Richard B Roth; Ugo Pastorino; Karl Haeussinger; Matthew R Nelson; Rainer Dierkesmann; Tommaso A Dragani; Andreas Braun Journal: J Clin Oncol Date: 2006-03-20 Impact factor: 44.544
Authors: William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus Journal: PLoS Med Date: 2005-02-22 Impact factor: 11.069
Authors: Ana Casal-Mouriño; Alberto Ruano-Ravina; María Lorenzo-González; Ángeles Rodríguez-Martínez; Alexandra Giraldo-Osorio; Leonor Varela-Lema; Tara Pereiro-Brea; Juan Miguel Barros-Dios; Luis Valdés-Cuadrado; Mónica Pérez-Ríos Journal: Transl Lung Cancer Res Date: 2021-01
Authors: Mariano Provencio; Josefa Terrasa; Pilar Garrido; Rosario García Campelo; Francisco Aparisi; Pilar Diz; David Aguiar; Carlos García-Giron; Julia Hidalgo; Carlos Aguado; Jorge García González; Emilio Esteban; Lorenzo Gómez-Aldavarí; Teresa Moran; Oscar Juan; Luís Enrique Chara; Juan L Marti; Rafael López Castro; Ana Laura Ortega; Elia Martínez Moreno; Juan Coves; Ana M Sánchez Peña; Joaquim Bosch-Barrera; Amparo Sánchez Gastaldo; Natalia Fernández Núñez; Edel Del Barco; Manuel Cobo; Dolores Isla; Margarita Majem; Fátima Navarro; Virginia Calvo Journal: BMC Cancer Date: 2021-03-06 Impact factor: 4.430
Authors: Alberto Ruano-Ravina; Mariano Provencio; Virginia Calvo de Juan; Enric Carcereny; Anna Estival; Delvys Rodríguez-Abreu; Gretel Benítez; Rafael López-Castro; Marta Belver; María Guirado-Risueño; Carlos Guirao-Rubio; Ana Blasco; Bartomeu Massutí; Ana Laura Ortega; Manuel Cobo; Joaquín Mosquera-Martínez; Carlos Aguado de la Rosa; Joaquim Bosch-Barrera; Amparo Sánchez-Gastaldo; Edel Del Barco Morillo; Óscar Juan; Manuel Dómine; José Manuel Trigo; Diego Pereiro Corbacho; Juana Oramas Journal: Transl Lung Cancer Res Date: 2021-10
Authors: Naghib Bogere; Felix Bongomin; Andrew Katende; Blair Andrew Omaido; Elizabeth Namukwaya; Harriet Mayanja-Kizza; Victoria Walusansa Journal: BMC Cancer Date: 2022-02-23 Impact factor: 4.430
Authors: Alberto Ruano-Raviña; Mariano Provencio; Virginia Calvo de Juan; Enric Carcereny; Teresa Moran; Delvys Rodriguez-Abreu; Rafael López-Castro; Eugenio Cuadrado Albite; María Guirado; Lucía Gómez González; Bartomeu Massutí; Ana Laura Ortega Granados; Ana Blasco; Manuel Cobo; Rosario Garcia-Campelo; Joaquim Bosch; José Trigo; Óscar Juan; Carlos Aguado de la Rosa; Manuel Dómine; María Sala; Juana Oramas; Joaquín Casal-Rubio; Sara Cerezo Journal: ESMO Open Date: 2020-11
Authors: Ernest Nadal; Dolores Bautista; Luis Cabezón-Gutiérrez; Ana Laura Ortega; Héctor Torres; David Carcedo; Lucía Ruiz de Alda; J Francisco Garcia; Paula Vieitez; Federico Rojo Journal: BMC Cancer Date: 2021-06-10 Impact factor: 4.430
Authors: Clara Salas; Javier Martín-López; Antonio Martínez-Pozo; Teresa Hernández-Iglesias; David Carcedo; Lucia Ruiz de Alda; J Francisco García; Federico Rojo Journal: J Clin Pathol Date: 2021-03-15 Impact factor: 3.411